Stock Market News2 days Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook Seeking Alpha
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook.
X4 hours Eli Lilly’s Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? Investor's Business Daily
X8 hours Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture YouTube
X8 hours Nvidia, Eli Lilly lead Friday’s market cap stock movers Investing.com
X9 hours There’s a New Obesity King The Wall Street Journal
X9 hours Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now Seeking Alpha
X12 hours LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List Zacks
X14 hours FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall Investing.com
X15 hours Novo Nordisk’s new weight-loss drug works better, but not as well as expected MarketWatch
X1 day Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over Investing.com
X1 day IBD 50’s Hims & Hers Tumbles After FDA Pulls Lilly’s Weight-Loss Drug From Shortage List Investor's Business Daily
X2 days FDA says Eli Lilly’s weight loss drug Zepbound is no longer in shortage CNBC
X3 days Eli Lilly’s Alzheimer’s treatment approved in China Investing.com
X3 days Eli Lilly Alzheimer’s drug donanemab approved in China Investing.com
X3 days Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know Zacks
X3 days NVS vs. LLY: Which Stock Should Value Investors Buy Now? Zacks
X4 days 15 Billion Reasons to Love Eli Lilly Stock Right Now Yahoo Finance
X4 days Eli Lilly: A Rare Buying Opportunity Seeking Alpha
X5 days Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? Investor's Business Daily
X5 days EMA Panel Endorses Lilly’s Omvoh for Expanded Use in Crohn’s Disease Zacks
X1 week Eli Lilly’s Manjaro gains on Novo Nordisk’s Wegovy in UK Investing.com
X1 week Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study Zacks
X1 week Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025 Yahoo Finance
X1 week Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade Zacks
X1 week Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly CNBC
X1 week Eli Lilly to test obesity drugs to treat addiction in 2025, CEO says #shorts #weightloss #zepbound YouTube
X1 week Eli Lilly to test obesity drugs for smoking, alcohol abuse – Bloomberg Investing.com
X2 weeks Oracle, AutoZone and Alaska Air fell premarket; Eli Lilly rose Investing.com
X2 weeks Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15% Zacks
X2 weeks The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group Zacks
X2 weeks Eli Lilly announces $15 billion buyback, dividend hike Investing.com
X2 weeks Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences Zacks
X2 weeks Netflix, Eli Lilly among Monday’s market cap stock movers Investing.com
X2 weeks Eli Lilly Stock Just Got Even Sweeter. Here’s Why It’s Worth Buying Now Yahoo Finance
X2 weeks The Zacks Analyst Blog Eli Lilly, Novo Nordisk’s Amgen and Viking Therapeutics Zacks
X2 weeks Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand Zacks
X2 weeks Pharma Stock Roundup: LLY’s Zepbound Success, FDA Updates for MRK, JNJ Zacks
X2 weeks How to Play LLY Stock as Zepbound Beats NVO’s Wegovy in Obesity Study Zacks
X2 weeks Eli Lilly Chief Scientific Officer explains Zepbound’s weight loss advantage YouTube
X2 weeks Prescription fills for weight loss drugs Zepbound, Wegovy more than doubled in 2024, GoodRx says CNBC
X2 weeks The Weight-Loss Battle That Could Rattle Eli Lilly’s $100 Billion Market Investor's Business Daily
X2 weeks LLY’s Zepbound Outshines NVO’s Wegovy in Head-to-Head Obesity Study Zacks
X2 weeks Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance The New York Times
X2 weeks Stocks making the biggest moves midday: JetBlue, Eli Lilly, Pure Storage, Salesforce and more CNBC
X2 weeks Eli Lilly says ‘Zepbound superior to Wegovy in head-to-head trial Investing.com
X2 weeks Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy MarketWatch
X2 weeks Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk Investor's Business Daily
X2 weeks Eli Lilly stock higher following surprise weight loss treatment data TheStreet
X2 weeks Eli Lilly Just Got a Bundle of Good News: Time to Buy? Yahoo Finance
X2 weeks Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial CNBC
X2 weeks Lightning Round: I prefer Eli Lilly over Regeneron YouTube
XThe Stock Market News
TheStockMarketNews.com is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live trading analysis, opinions and forecasts on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds, rates and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.